8:50 am Chair’s Opening Remarks
9:00 am Updates on Non-Oral JAKi Therapy: Unique Challenges & Interest
Synopsis
- Outlining current challenges and opportunities with alternative JAKi application
- Sharing insights from multidisciplinary backgrounds and application experience
- Speculating on the upcoming therapeutic landscape and potential for alternative JAKi intervention
Determine the Therapeutic Potential of JAK Inhibitors for Dermatological Disease
9:45 am The Emerging Evidence for the Use of JAK Inhibitors in Connective Tissue Diseases (CTDs)
Synopsis
- Detailing the basic science and rationale
- Providing anecdotal evidence and case reports
- Updating and describing ongoing clinical trials
10:10 am The Evolving Landscape of JAK Inhibitors for Chronic Itch
Synopsis
- Introduce scientific findings related to how JAKs mediate itch
- Overview of itch outcomes in AD trials
- New clinical studies on new indications for cytokine blockade and JAK inhibition in chronic itch
10:35 am Targeting JAK Signalling in the Treatment of Vitiligo
Synopsis
- Overview of vitiligo pathogenesis, psychosocial comorbidities and unmet medical need
- Discuss vitiligo competitive landscape, current challenges in conducting vitiligo clinical trials and regulatory path
- Demonstrate efficacy and safety of ruxolitinib (JAK inhibitor) cream and discuss subgroup analysis based on patient demographics and clinical characteristics from a phase 2 vitiligo clinical trial
11:00 am Speaker Q&A panel
11:15 am Virtual Speed Networking
11:45 am Coffee Break
11:55 am Update on Long-Term Safety & Efficacy of CTP-543, an Oral JAK Inhibitor, for the Treatment of Alopecia Areata
Synopsis
- CTP-543 was dosed for 24 weeks in three Phase 2 trials; eligible patients subsequently enrolled in a long-term, open-label extension trial with >130 patients treated for more than 1 year.
- Hair regrowth assessed by SALT has been sustained or improved in the vast majority of patients in the extension study relative to the Phase 2 results
- Treatment with CTP-543 continues to be generally well tolerated, with a safety profile similar to that observed in Phase 2.
12:20 pm The Dual Inhibition of SYK & JAK Kinases for the Treatment of Skin & Complex Inflammatory Conditions
Synopsis
- Addressing novel treatments in Chronic Hand Eczema as therapy gusacitinib, a dual SYK/JAK inhibitor, advances to phase 3 clinical development.
- Evaluating additional role of TYK2 and SYK in epithelial cell/keratinocyte function
- Detailing further potential in dermatologic and immunologic condition
12:45 pm A Model for Polyautoimmune & Inflammatory Disease & its Treatment with JAK Inhibitors
Synopsis
- Addressing the poorly understood treatment of patients with multiple autoimmune and inflammatory diseases
- Developing a model for polyautoimmune and inflammatory disease and its treatment
- Describing the potential of JAK inhibitors for the treatment of complex patients with polyautoimmune and inflammatory disease
1:10 pm Speaker Q&A panel
1:25 pm Lunch
Highlighting the Efficacious & Widely Applicable JAK Inhibitor in Other Specialities to Provide Wider Clinical Insight
2:25 pm Exploring the Role of JAK Inhibition in the Treatment of Sarcoidosis & Other Granulomatous Disorders
Synopsis
- Addressing the difficulties in treating granulomatous inflammatory disorders, including sarcoidosis
- There is emerging evidence that JAK inhibition may be a promising treatment approach in sarcoidosis, granuloma annulare, and other granulomatous disorders
- Efficacy data and key cytokine targets of JAK inhibitors in sarcoidosis and other granulomatous disorders will be discussed
2:50 pm Reistone Biopharma’s Pursuit into Ulcerative Colitis Using a – JAK 1 Inhibitor – a Successful Case Study
Synopsis
- Describing the latest RSJ10101 results from in UC therapy
- Defining the drug MOA, clinical endpoints used, and overcoming operational challenges in a UC study
- Looking forward towards future studies and correlating progress with other disease
3:15 pm Momelotinib as a Differentiated JAK Inhibitor for Myelofibrosis
Synopsis
- Describing the significant unmet needs in myelofibrosis which include the need for durable benefits and longer survival, improved anemia and transfusion requirements, and benefit in patients with thrombocytopenia
- Detailing how potent inhibition of ACVR1, in addition to JAK1 and JAK2 inhibition, can reduce or eliminate the need for transfusion, potentially leading to improved overall survival
- Based on the differentiated hematologic safety profile, momelotinib has the potential to become a combination agent of choice